Kartläggning av bioproduktion i Sverige : Behov, hinder och drivkrafter

The market for drugs and treatments using biological products is rapidly growing. This is mainly due to the great potential that biological products have in comparison to traditional drugs. Biological products are composed of bigger molecules such as proteins and antibodies, and therefore allow a much more specific treatment. With the complexity of the molecules comes complexity in the upscaling of manufacturing. Start-up companies tend to lack knowledge of this process; consequently, outsourcing is often a requirement for the companies to grow. Outsourcing can be both risky and costly and the companies could benefit from having the skills in-house instead. This report provides information about needs, obstacles and driving forces regarding the future market for biological medicine and also outsourcing’s effect on the market. Desktop research was used to provide necessary information about the market and biological medicines, and also to find companies, research groups and investors that we mapped according to parameters, such as location and what field of medicine they engage in. Through phone and email contact, we gained further understanding about the actors we targeted. Desktop research and interviews were used to identify needs, obstacles and driving forces regarding the development of biological medicine. The result gives insight into where in Sweden the different candidates operate and it tells what pursuits and holdbacks they are facing when developing biological medicines. The major driving force is providing patients efficient treatments but also the opportunity to capitalise in a novel and successful type of industry. The major obstacle is first and foremost the great amount of money needed. Also, companies fail to grasp the many complex and time consuming steps in developing biological medicines. The interviews also showed that outsourcing is practically inevitable, especially for small companies, due to the difficulties of concentrating the competence in-house. In conclusion, the report shows that the benefits of biological medicine creates great driving forces for its development and that Sweden makes up a good climate for this. It also enlightens the importance of test beds to ensure that the future development relies on competence